Longzhibu disease and its therapeutic effects by traditional Tibetan medicine: Ershi-wei Chenxiang pills

Ershi-wei Chenxiang pills (ECP) or Aga Nixiu wan (ཨ་གར་ཉི་ཤུ།), composed of 20 Tibetan medicines, has the effect of promoting blood circulation to remove blood stasis. As a common and frequent prescription used by traditional Tibetan medicine in clinical treatment of Longzhibu disease (cerebral isch...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of ethnopharmacology 2020-03, Vol.249, p.112426-112426, Article 112426
Hauptverfasser: Hou, Ya, Qieni, Xiangmao, Li, Ning, Bai, Jinrong, Li, Rui, Gongbao, Dongzhi, Liang, Yusheng, Fan, Fangfang, Wencheng, Dangzhi, Wang, Zhang, Nima, Ciren, Meng, Xianli, Zhang, Yi, Wang, Xiaobo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 112426
container_issue
container_start_page 112426
container_title Journal of ethnopharmacology
container_volume 249
creator Hou, Ya
Qieni, Xiangmao
Li, Ning
Bai, Jinrong
Li, Rui
Gongbao, Dongzhi
Liang, Yusheng
Fan, Fangfang
Wencheng, Dangzhi
Wang, Zhang
Nima, Ciren
Meng, Xianli
Zhang, Yi
Wang, Xiaobo
description Ershi-wei Chenxiang pills (ECP) or Aga Nixiu wan (ཨ་གར་ཉི་ཤུ།), composed of 20 Tibetan medicines, has the effect of promoting blood circulation to remove blood stasis. As a common and frequent prescription used by traditional Tibetan medicine in clinical treatment of Longzhibu disease (cerebral ischemia sequelae), it has a significant effect. However, its anti-cerebral ischemia mechanism is still unclear. The chemical components of ECP were determined by high-performance liquid chromatography and gas chromatography–mass spectrometry. SD rats were randomly divided into Sham, MCAO, Nim (20.00 mg/kg), and ECP (1.33 and 2.00 g/kg) groups, with 13 animals in each group. After 14 days of oral administration, we established a model of cerebral ischemia reperfusion injury by blocking the middle cerebral artery of rats. After 24 h of reperfusion injury, we evaluated the protective effect of ECP on ischemic brain by neural function score, TTC, H&E and Nissl staining. TUNEL fluorescence, western blot and immunohistochemistry were used to detect the phenomenon of apoptosis and the expression of apoptosis-related proteins Bax, Bcl-2, Cyto-c and activated Caspase-3. Furthermore, western blot, qRT-PCR and immunohistochemistry were employed to detect CaMKⅡ, ATF4 and c-Jun gene and protein expression. ECP contains agarotetrol, eugenol, oleanolic acid, ursolic acid, dehydrodiisoeugenol, hydroxysafflor yellow A, kaempferide, gallic acid, alantolactone, isoalantolactone, costunolide, dehydrocostus lactone, brucine, strychnine, echinacoside, bilirubin and cholic acid. Compared with MCAO group, ECP can significantly ameliorate the neurological deficit of cerebral ischemia in rats and reduce the volume of cerebral infarction. Pathological and Nissl staining results showed that ECP sharply inhibited the inflammatory infiltration injury of neurons and increased the activity of neurons in comparation with the MCAO group. TUNEL fluorescence apoptosis results confirmed that ECP obviously inhibited the apoptosis of neurons. Meanwhile, the results of immunohistochemistry and western blot demonstrated that EPC can dramatically inhibit the expression of pro-apoptotic proteins Bax, Cyto-c and activated Caspase-3, while increase the level of anti-apoptotic protein Bcl-2. In addition, compared with MCAO group, CaMK Ⅱ gene and protein expression were improved significantly by ECP administration. while, the expression of ATF4 and c-Jun genes and proteins were decreased. In conclusion, this st
doi_str_mv 10.1016/j.jep.2019.112426
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2319501039</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378874119333409</els_id><sourcerecordid>2319501039</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-3d092050627ab69ac56898db8aff3a2a7a7a88cb782e394ed14e9c4cf262ad3b3</originalsourceid><addsrcrecordid>eNp9kE1P3DAQhi3UCraUH8AF-dhLtv5IYoee0ApKpZV6oWfLsSdkVlkn2En5-PUYLfRYzWGk0TOv9D6EnHO25ozX33frHUxrwXiz5lyUoj4iK66VKFSl5CeyYlLpQquSn5AvKe0YY4qX7JicSK5UxThfkX47hvuXHtuFekxgE1AbPMU50bmHaCdYZnQUug5cvrXPdI7W44xjsAO9wxZmG-gePDoMcEmvY-qxeASkmx7CE9pwTycchvSVfO7skODsfZ-SPzfXd5vbYvv756_N1bZwspJzIT1rBKtYLZRt68a6qtaN9q22XSetsCqP1q5VWoBsSvC8hMaVrhO1sF628pR8O-ROcXxYIM1mj8nBMNgA45KMkLzJ1ZlsMsoPqItjShE6M0Xc2_hsODNvgs3OZMHmTbA5CM4_F-_xS5tb__v4MJqBHwcAcsm_CNEkhxBcNhSzQuNH_E_8K_-kjIU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2319501039</pqid></control><display><type>article</type><title>Longzhibu disease and its therapeutic effects by traditional Tibetan medicine: Ershi-wei Chenxiang pills</title><source>Elsevier ScienceDirect Journals</source><creator>Hou, Ya ; Qieni, Xiangmao ; Li, Ning ; Bai, Jinrong ; Li, Rui ; Gongbao, Dongzhi ; Liang, Yusheng ; Fan, Fangfang ; Wencheng, Dangzhi ; Wang, Zhang ; Nima, Ciren ; Meng, Xianli ; Zhang, Yi ; Wang, Xiaobo</creator><creatorcontrib>Hou, Ya ; Qieni, Xiangmao ; Li, Ning ; Bai, Jinrong ; Li, Rui ; Gongbao, Dongzhi ; Liang, Yusheng ; Fan, Fangfang ; Wencheng, Dangzhi ; Wang, Zhang ; Nima, Ciren ; Meng, Xianli ; Zhang, Yi ; Wang, Xiaobo</creatorcontrib><description>Ershi-wei Chenxiang pills (ECP) or Aga Nixiu wan (ཨ་གར་ཉི་ཤུ།), composed of 20 Tibetan medicines, has the effect of promoting blood circulation to remove blood stasis. As a common and frequent prescription used by traditional Tibetan medicine in clinical treatment of Longzhibu disease (cerebral ischemia sequelae), it has a significant effect. However, its anti-cerebral ischemia mechanism is still unclear. The chemical components of ECP were determined by high-performance liquid chromatography and gas chromatography–mass spectrometry. SD rats were randomly divided into Sham, MCAO, Nim (20.00 mg/kg), and ECP (1.33 and 2.00 g/kg) groups, with 13 animals in each group. After 14 days of oral administration, we established a model of cerebral ischemia reperfusion injury by blocking the middle cerebral artery of rats. After 24 h of reperfusion injury, we evaluated the protective effect of ECP on ischemic brain by neural function score, TTC, H&amp;E and Nissl staining. TUNEL fluorescence, western blot and immunohistochemistry were used to detect the phenomenon of apoptosis and the expression of apoptosis-related proteins Bax, Bcl-2, Cyto-c and activated Caspase-3. Furthermore, western blot, qRT-PCR and immunohistochemistry were employed to detect CaMKⅡ, ATF4 and c-Jun gene and protein expression. ECP contains agarotetrol, eugenol, oleanolic acid, ursolic acid, dehydrodiisoeugenol, hydroxysafflor yellow A, kaempferide, gallic acid, alantolactone, isoalantolactone, costunolide, dehydrocostus lactone, brucine, strychnine, echinacoside, bilirubin and cholic acid. Compared with MCAO group, ECP can significantly ameliorate the neurological deficit of cerebral ischemia in rats and reduce the volume of cerebral infarction. Pathological and Nissl staining results showed that ECP sharply inhibited the inflammatory infiltration injury of neurons and increased the activity of neurons in comparation with the MCAO group. TUNEL fluorescence apoptosis results confirmed that ECP obviously inhibited the apoptosis of neurons. Meanwhile, the results of immunohistochemistry and western blot demonstrated that EPC can dramatically inhibit the expression of pro-apoptotic proteins Bax, Cyto-c and activated Caspase-3, while increase the level of anti-apoptotic protein Bcl-2. In addition, compared with MCAO group, CaMK Ⅱ gene and protein expression were improved significantly by ECP administration. while, the expression of ATF4 and c-Jun genes and proteins were decreased. In conclusion, this study preliminarily demonstrated that the protective effect of ECP on ischemic brain is related to the improvement of neurological deficit, reducing the size of cerebral infarction, improving the activity of neurons, inhibiting the mitochondrial apoptosis pathway by regulating the protein expression of CaMKⅡ, ATF4 and c-Jun. However, further in vivo and in vitro investigations are still needed to clarify the underlying mechanism of ECP in treating cerebral ischemia sequelae. [Display omitted]</description><identifier>ISSN: 0378-8741</identifier><identifier>EISSN: 1872-7573</identifier><identifier>DOI: 10.1016/j.jep.2019.112426</identifier><identifier>PMID: 31775011</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Apoptosis ; Ershi-wei Chenxiang pills ; Ischemic stroke ; Longzhibu disease ; MCAO ; Tibetan medicine</subject><ispartof>Journal of ethnopharmacology, 2020-03, Vol.249, p.112426-112426, Article 112426</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-3d092050627ab69ac56898db8aff3a2a7a7a88cb782e394ed14e9c4cf262ad3b3</citedby><cites>FETCH-LOGICAL-c353t-3d092050627ab69ac56898db8aff3a2a7a7a88cb782e394ed14e9c4cf262ad3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0378874119333409$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31775011$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hou, Ya</creatorcontrib><creatorcontrib>Qieni, Xiangmao</creatorcontrib><creatorcontrib>Li, Ning</creatorcontrib><creatorcontrib>Bai, Jinrong</creatorcontrib><creatorcontrib>Li, Rui</creatorcontrib><creatorcontrib>Gongbao, Dongzhi</creatorcontrib><creatorcontrib>Liang, Yusheng</creatorcontrib><creatorcontrib>Fan, Fangfang</creatorcontrib><creatorcontrib>Wencheng, Dangzhi</creatorcontrib><creatorcontrib>Wang, Zhang</creatorcontrib><creatorcontrib>Nima, Ciren</creatorcontrib><creatorcontrib>Meng, Xianli</creatorcontrib><creatorcontrib>Zhang, Yi</creatorcontrib><creatorcontrib>Wang, Xiaobo</creatorcontrib><title>Longzhibu disease and its therapeutic effects by traditional Tibetan medicine: Ershi-wei Chenxiang pills</title><title>Journal of ethnopharmacology</title><addtitle>J Ethnopharmacol</addtitle><description>Ershi-wei Chenxiang pills (ECP) or Aga Nixiu wan (ཨ་གར་ཉི་ཤུ།), composed of 20 Tibetan medicines, has the effect of promoting blood circulation to remove blood stasis. As a common and frequent prescription used by traditional Tibetan medicine in clinical treatment of Longzhibu disease (cerebral ischemia sequelae), it has a significant effect. However, its anti-cerebral ischemia mechanism is still unclear. The chemical components of ECP were determined by high-performance liquid chromatography and gas chromatography–mass spectrometry. SD rats were randomly divided into Sham, MCAO, Nim (20.00 mg/kg), and ECP (1.33 and 2.00 g/kg) groups, with 13 animals in each group. After 14 days of oral administration, we established a model of cerebral ischemia reperfusion injury by blocking the middle cerebral artery of rats. After 24 h of reperfusion injury, we evaluated the protective effect of ECP on ischemic brain by neural function score, TTC, H&amp;E and Nissl staining. TUNEL fluorescence, western blot and immunohistochemistry were used to detect the phenomenon of apoptosis and the expression of apoptosis-related proteins Bax, Bcl-2, Cyto-c and activated Caspase-3. Furthermore, western blot, qRT-PCR and immunohistochemistry were employed to detect CaMKⅡ, ATF4 and c-Jun gene and protein expression. ECP contains agarotetrol, eugenol, oleanolic acid, ursolic acid, dehydrodiisoeugenol, hydroxysafflor yellow A, kaempferide, gallic acid, alantolactone, isoalantolactone, costunolide, dehydrocostus lactone, brucine, strychnine, echinacoside, bilirubin and cholic acid. Compared with MCAO group, ECP can significantly ameliorate the neurological deficit of cerebral ischemia in rats and reduce the volume of cerebral infarction. Pathological and Nissl staining results showed that ECP sharply inhibited the inflammatory infiltration injury of neurons and increased the activity of neurons in comparation with the MCAO group. TUNEL fluorescence apoptosis results confirmed that ECP obviously inhibited the apoptosis of neurons. Meanwhile, the results of immunohistochemistry and western blot demonstrated that EPC can dramatically inhibit the expression of pro-apoptotic proteins Bax, Cyto-c and activated Caspase-3, while increase the level of anti-apoptotic protein Bcl-2. In addition, compared with MCAO group, CaMK Ⅱ gene and protein expression were improved significantly by ECP administration. while, the expression of ATF4 and c-Jun genes and proteins were decreased. In conclusion, this study preliminarily demonstrated that the protective effect of ECP on ischemic brain is related to the improvement of neurological deficit, reducing the size of cerebral infarction, improving the activity of neurons, inhibiting the mitochondrial apoptosis pathway by regulating the protein expression of CaMKⅡ, ATF4 and c-Jun. However, further in vivo and in vitro investigations are still needed to clarify the underlying mechanism of ECP in treating cerebral ischemia sequelae. [Display omitted]</description><subject>Apoptosis</subject><subject>Ershi-wei Chenxiang pills</subject><subject>Ischemic stroke</subject><subject>Longzhibu disease</subject><subject>MCAO</subject><subject>Tibetan medicine</subject><issn>0378-8741</issn><issn>1872-7573</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1P3DAQhi3UCraUH8AF-dhLtv5IYoee0ApKpZV6oWfLsSdkVlkn2En5-PUYLfRYzWGk0TOv9D6EnHO25ozX33frHUxrwXiz5lyUoj4iK66VKFSl5CeyYlLpQquSn5AvKe0YY4qX7JicSK5UxThfkX47hvuXHtuFekxgE1AbPMU50bmHaCdYZnQUug5cvrXPdI7W44xjsAO9wxZmG-gePDoMcEmvY-qxeASkmx7CE9pwTycchvSVfO7skODsfZ-SPzfXd5vbYvv756_N1bZwspJzIT1rBKtYLZRt68a6qtaN9q22XSetsCqP1q5VWoBsSvC8hMaVrhO1sF628pR8O-ROcXxYIM1mj8nBMNgA45KMkLzJ1ZlsMsoPqItjShE6M0Xc2_hsODNvgs3OZMHmTbA5CM4_F-_xS5tb__v4MJqBHwcAcsm_CNEkhxBcNhSzQuNH_E_8K_-kjIU</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Hou, Ya</creator><creator>Qieni, Xiangmao</creator><creator>Li, Ning</creator><creator>Bai, Jinrong</creator><creator>Li, Rui</creator><creator>Gongbao, Dongzhi</creator><creator>Liang, Yusheng</creator><creator>Fan, Fangfang</creator><creator>Wencheng, Dangzhi</creator><creator>Wang, Zhang</creator><creator>Nima, Ciren</creator><creator>Meng, Xianli</creator><creator>Zhang, Yi</creator><creator>Wang, Xiaobo</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200301</creationdate><title>Longzhibu disease and its therapeutic effects by traditional Tibetan medicine: Ershi-wei Chenxiang pills</title><author>Hou, Ya ; Qieni, Xiangmao ; Li, Ning ; Bai, Jinrong ; Li, Rui ; Gongbao, Dongzhi ; Liang, Yusheng ; Fan, Fangfang ; Wencheng, Dangzhi ; Wang, Zhang ; Nima, Ciren ; Meng, Xianli ; Zhang, Yi ; Wang, Xiaobo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-3d092050627ab69ac56898db8aff3a2a7a7a88cb782e394ed14e9c4cf262ad3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Apoptosis</topic><topic>Ershi-wei Chenxiang pills</topic><topic>Ischemic stroke</topic><topic>Longzhibu disease</topic><topic>MCAO</topic><topic>Tibetan medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hou, Ya</creatorcontrib><creatorcontrib>Qieni, Xiangmao</creatorcontrib><creatorcontrib>Li, Ning</creatorcontrib><creatorcontrib>Bai, Jinrong</creatorcontrib><creatorcontrib>Li, Rui</creatorcontrib><creatorcontrib>Gongbao, Dongzhi</creatorcontrib><creatorcontrib>Liang, Yusheng</creatorcontrib><creatorcontrib>Fan, Fangfang</creatorcontrib><creatorcontrib>Wencheng, Dangzhi</creatorcontrib><creatorcontrib>Wang, Zhang</creatorcontrib><creatorcontrib>Nima, Ciren</creatorcontrib><creatorcontrib>Meng, Xianli</creatorcontrib><creatorcontrib>Zhang, Yi</creatorcontrib><creatorcontrib>Wang, Xiaobo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of ethnopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hou, Ya</au><au>Qieni, Xiangmao</au><au>Li, Ning</au><au>Bai, Jinrong</au><au>Li, Rui</au><au>Gongbao, Dongzhi</au><au>Liang, Yusheng</au><au>Fan, Fangfang</au><au>Wencheng, Dangzhi</au><au>Wang, Zhang</au><au>Nima, Ciren</au><au>Meng, Xianli</au><au>Zhang, Yi</au><au>Wang, Xiaobo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longzhibu disease and its therapeutic effects by traditional Tibetan medicine: Ershi-wei Chenxiang pills</atitle><jtitle>Journal of ethnopharmacology</jtitle><addtitle>J Ethnopharmacol</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>249</volume><spage>112426</spage><epage>112426</epage><pages>112426-112426</pages><artnum>112426</artnum><issn>0378-8741</issn><eissn>1872-7573</eissn><abstract>Ershi-wei Chenxiang pills (ECP) or Aga Nixiu wan (ཨ་གར་ཉི་ཤུ།), composed of 20 Tibetan medicines, has the effect of promoting blood circulation to remove blood stasis. As a common and frequent prescription used by traditional Tibetan medicine in clinical treatment of Longzhibu disease (cerebral ischemia sequelae), it has a significant effect. However, its anti-cerebral ischemia mechanism is still unclear. The chemical components of ECP were determined by high-performance liquid chromatography and gas chromatography–mass spectrometry. SD rats were randomly divided into Sham, MCAO, Nim (20.00 mg/kg), and ECP (1.33 and 2.00 g/kg) groups, with 13 animals in each group. After 14 days of oral administration, we established a model of cerebral ischemia reperfusion injury by blocking the middle cerebral artery of rats. After 24 h of reperfusion injury, we evaluated the protective effect of ECP on ischemic brain by neural function score, TTC, H&amp;E and Nissl staining. TUNEL fluorescence, western blot and immunohistochemistry were used to detect the phenomenon of apoptosis and the expression of apoptosis-related proteins Bax, Bcl-2, Cyto-c and activated Caspase-3. Furthermore, western blot, qRT-PCR and immunohistochemistry were employed to detect CaMKⅡ, ATF4 and c-Jun gene and protein expression. ECP contains agarotetrol, eugenol, oleanolic acid, ursolic acid, dehydrodiisoeugenol, hydroxysafflor yellow A, kaempferide, gallic acid, alantolactone, isoalantolactone, costunolide, dehydrocostus lactone, brucine, strychnine, echinacoside, bilirubin and cholic acid. Compared with MCAO group, ECP can significantly ameliorate the neurological deficit of cerebral ischemia in rats and reduce the volume of cerebral infarction. Pathological and Nissl staining results showed that ECP sharply inhibited the inflammatory infiltration injury of neurons and increased the activity of neurons in comparation with the MCAO group. TUNEL fluorescence apoptosis results confirmed that ECP obviously inhibited the apoptosis of neurons. Meanwhile, the results of immunohistochemistry and western blot demonstrated that EPC can dramatically inhibit the expression of pro-apoptotic proteins Bax, Cyto-c and activated Caspase-3, while increase the level of anti-apoptotic protein Bcl-2. In addition, compared with MCAO group, CaMK Ⅱ gene and protein expression were improved significantly by ECP administration. while, the expression of ATF4 and c-Jun genes and proteins were decreased. In conclusion, this study preliminarily demonstrated that the protective effect of ECP on ischemic brain is related to the improvement of neurological deficit, reducing the size of cerebral infarction, improving the activity of neurons, inhibiting the mitochondrial apoptosis pathway by regulating the protein expression of CaMKⅡ, ATF4 and c-Jun. However, further in vivo and in vitro investigations are still needed to clarify the underlying mechanism of ECP in treating cerebral ischemia sequelae. [Display omitted]</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>31775011</pmid><doi>10.1016/j.jep.2019.112426</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-8741
ispartof Journal of ethnopharmacology, 2020-03, Vol.249, p.112426-112426, Article 112426
issn 0378-8741
1872-7573
language eng
recordid cdi_proquest_miscellaneous_2319501039
source Elsevier ScienceDirect Journals
subjects Apoptosis
Ershi-wei Chenxiang pills
Ischemic stroke
Longzhibu disease
MCAO
Tibetan medicine
title Longzhibu disease and its therapeutic effects by traditional Tibetan medicine: Ershi-wei Chenxiang pills
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T21%3A38%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longzhibu%20disease%20and%20its%20therapeutic%20effects%20by%20traditional%20Tibetan%20medicine:%20Ershi-wei%20Chenxiang%20pills&rft.jtitle=Journal%20of%20ethnopharmacology&rft.au=Hou,%20Ya&rft.date=2020-03-01&rft.volume=249&rft.spage=112426&rft.epage=112426&rft.pages=112426-112426&rft.artnum=112426&rft.issn=0378-8741&rft.eissn=1872-7573&rft_id=info:doi/10.1016/j.jep.2019.112426&rft_dat=%3Cproquest_cross%3E2319501039%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2319501039&rft_id=info:pmid/31775011&rft_els_id=S0378874119333409&rfr_iscdi=true